Baloxavir marboxil

Active ingredient description

Baloxavir marboxil is a prodrug that is converted by hydrolysis to baloxavir, the active form that exerts anti-influenza activity. Baloxavir acts on the cap-dependent endonuclease (CEN), an influenza virus-specific enzyme in the polymerase acidic (PA) subunit of the viral RNA polymerase complex and thereby inhibits the transcription of influenza virus genomes resulting in inhibition of influenza virus replication.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
J05AX25
Baloxavir marboxil
J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX25

Medicines

Baloxavir marboxil is the active ingredient of these drugs:

Drug
Countries
XOFLUZA

Austria Finland Hong Kong Ireland Lithuania

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
XOFLUZA Film-coated tablet
Summary of Product Characteristics (SPC)
XOFLUZA Film-coated tablet
Structured Product Labeling (SPL/PLR)
US

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

505CXM6OHG - BALOXAVIR MARBOXIL

SNOMED-CT

782500006 - Baloxavir marboxil (substance)

Next: Usage